{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:53:05Z","timestamp":1790837585629,"version":"4.1.0"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2016,8,3]],"date-time":"2016-08-03T00:00:00Z","timestamp":1470182400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"This article did not receive any form of funding."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1007\/s00415-016-8244-7","type":"journal-article","created":{"date-parts":[[2016,8,3]],"date-time":"2016-08-03T09:40:09Z","timestamp":1470217209000},"page":"2170-2178","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Long-term treatment with thiamine as possible medical therapy for Friedreich ataxia"],"prefix":"10.1007","volume":"263","author":[{"given":"Antonio","family":"Costantini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiziana","family":"Laureti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Immacolata","family":"Pala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Colangeli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Cavalieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Pozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Brusco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandro","family":"Salvarani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Serrati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Fancellu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,8,3]]},"reference":[{"key":"8244_CR1","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/B978-0-444-51892-7.00017-6","volume":"103","author":"M Pandolfo","year":"2012","unstructured":"Pandolfo M (2012) Friedreich ataxia. Handb Clin Neurol 103:275\u2013294","journal-title":"Handb Clin Neurol"},{"issue":"5","key":"8244_CR2","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.neurol.2014.03.008","volume":"170","author":"H Puccio","year":"2014","unstructured":"Puccio H, Anheim M, Tranchant C (2014) Pathophysiogical and therapeutic progress in Friedreich ataxia. Rev Neurol (Paris) 170(5):355\u2013365","journal-title":"Rev Neurol (Paris)"},{"issue":"4","key":"8244_CR3","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1016\/j.ncl.2013.05.002","volume":"31","author":"A Collins","year":"2013","unstructured":"Collins A (2013) Clinical neurogenetics: friedreich ataxia. Neurol Clin 31(4):1095\u20131120","journal-title":"Neurol Clin"},{"issue":"9","key":"8244_CR4","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1186\/s13023-014-0184-7","volume":"30","author":"LA Corben","year":"2014","unstructured":"Corben LA, Lynch D, Pandolfo M, Schulz JB, Delatycki MB, Clinical Management Guidelines Writing Group (2014) Consensus clinical management guidelines for Friedreich ataxia. Orphanet J Rare Dis 30(9):184. doi: 10.1186\/s13023-014-0184-7","journal-title":"Orphanet J Rare Dis"},{"issue":"2","key":"8244_CR5","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1007\/s12311-013-0531-6","volume":"13","author":"W Ilg","year":"2014","unstructured":"Ilg W, Bastian AJ, Boesch S, Burciu RG, Celnik P, Claa\u00dfen J, Feil K, Kalla R, Miyai I, Nachbauer W, Sch\u00f6ls L, Strupp M, Synofzik M, Teufel J, Timmann D (2014) Consensus paper: management of degenerative cerebellar disorders. Cerebellum 13(2):248\u2013268. doi: 10.1007\/s12311-013-0531-6","journal-title":"Cerebellum"},{"key":"8244_CR6","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/S1474-4422(07)70104-7","volume":"6","author":"G Sechi","year":"2007","unstructured":"Sechi G, Serra A (2007) Wernicke\u2019s encephalopathy: new clinical settings and recent advances in diagnosis and management. Lancet Neurol 6:442\u2013455","journal-title":"Lancet Neurol"},{"issue":"1","key":"8244_CR7","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1080\/14734220600551707","volume":"5","author":"PJ Mulholland","year":"2006","unstructured":"Mulholland PJ (2006) Susceptibility of the cerebellum to thiamine deficiency. Cerebellum 5(1):55\u201363","journal-title":"Cerebellum"},{"issue":"4","key":"8244_CR8","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/j.ncl.2014.07.001","volume":"32","author":"N Alekseeva","year":"2014","unstructured":"Alekseeva N, McGee J, Kelley RE, Maghzi AH, Gonzalez-Toledo E, Minagar A (2014) Toxic-metabolic, nutritional, and medicinal-induced disorders of cerebellum. Neurol Clin 32(4):901\u2013911","journal-title":"Neurol Clin"},{"key":"8244_CR9","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.neuint.2010.11.019","volume":"58","author":"SS Jhala","year":"2011","unstructured":"Jhala SS, Hazell AS (2011) Modeling neurodegenerative disease pathophysiology in thiamine deficiency: consequences of impaired oxidative metabolism. Neurochem Int 58:248\u2013260","journal-title":"Neurochem Int"},{"key":"8244_CR10","doi-asserted-by":"crossref","first-page":"12583","DOI":"10.1038\/srep12583","volume":"27","author":"G Mkrtchyan","year":"2015","unstructured":"Mkrtchyan G, Aleshin V, Parkhomenko Y, Kaehne T, Luigi Di Salvo M, Parroni A, Contestabile R, Vovk A, Bettendorff L, Bunik V (2015) Molecular mechanisms of the non-coenzyme action of thiamin in brain: biochemical, structural and pathway analysis. Sci Rep 27:12583","journal-title":"Sci Rep"},{"issue":"10","key":"8244_CR11","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1089\/ars.2007.1766","volume":"9","author":"GE Gibson","year":"2007","unstructured":"Gibson GE, Blass JP (2007) Thiamine-dependent processes and treatment strategies in neurodegeneration. Antioxid Redox Signal 9(10):1605\u20131619","journal-title":"Antioxid Redox Signal"},{"key":"8244_CR12","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/B978-0-7020-4087-0.00042-5","volume":"120","author":"RF Pfeiffer","year":"2014","unstructured":"Pfeiffer RF (2014) Neurologic manifestations of malabsorption syndromes. Handb Clin Neurol 120:621\u2013632","journal-title":"Handb Clin Neurol"},{"key":"8244_CR13","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1079\/NRR200367","volume":"16","author":"RF Butterworth","year":"2003","unstructured":"Butterworth RF (2003) Thiamin deficiency and brain disorders. Nutr Res Rev 16:277\u2013284","journal-title":"Nutr Res Rev"},{"issue":"2","key":"8244_CR14","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1136\/jnnp.55.2.136","volume":"55","author":"OL Pedraza","year":"1992","unstructured":"Pedraza OL, Botez MI (1992) Thiamine status in inherited degenerative ataxias. J Neurol Neurosurg Psychiatry 55(2):136\u2013137","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3","key":"8244_CR15","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1159\/000116814","volume":"32","author":"M Poloni","year":"1992","unstructured":"Poloni M, Mazzarello P, Laforenza U, Caramella C, Patrini C (1992) Thiamin contents of cerebrospinal fluid, plasma and erythrocytes in cerebellar ataxias. Eur Neurol 32(3):154\u2013158","journal-title":"Eur Neurol"},{"issue":"2","key":"8244_CR16","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1017\/S0317167100052811","volume":"28","author":"MI Botez","year":"2001","unstructured":"Botez MI, Young SN (2001) Biogenic amine metabolites and thiamine in cerebrospinal fluid in heredo-degenerative ataxias. Can J Neurol Sci 28(2):134\u2013140","journal-title":"Can J Neurol Sci"},{"issue":"4","key":"8244_CR17","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1017\/S0317167100025634","volume":"3","author":"A Barbeau","year":"1976","unstructured":"Barbeau A, Butterworth RF, Ngo T, Breton G, Melan\u00e7on S, Shapcott D, Geoffroy G, Lemieux B (1976) Pyruvate metabolism in Friedreich\u2019s ataxia. Can J Neurol Sci 3(4):379\u2013388","journal-title":"Can J Neurol Sci"},{"key":"8244_CR18","first-page":"163","volume":"21","author":"RA Kark","year":"1978","unstructured":"Kark RA, Rodriguez-Budelli M, Blass JP (1978) Evidence for a primary defect of lipoamide dehydrogenase in Friedreich\u2019s ataxia. Adv Neurol 21:163\u2013180","journal-title":"Adv Neurol"},{"key":"8244_CR19","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1136\/jnnp.44.7.574","volume":"44","author":"P Purkiss","year":"1981","unstructured":"Purkiss P, Baraitser M, Borud O, Chalmers RA (1981) Biochemical and clinical studies in Friedreich\u2019s ataxia. J Neurol Neurosurg Psychiatry 44:574\u2013580","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"8244_CR20","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1136\/jnnp.47.1.111","volume":"47","author":"RF Gledhill","year":"1984","unstructured":"Gledhill RF, Labadarios D (1984) Biochemical vitamin deficiencies in Friedreich\u2019s ataxia. J Neurol Neurosurg Psychiatry 47(1):111\u2013112","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"8244_CR21","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2013-009424","author":"A Costantini","year":"2013","unstructured":"Costantini A, Giorgi R, D\u2019Agostino S, Pala MI (2013) High dose thiamine improves the symptoms of Friedreich\u2019s ataxia. BMJ Case Rep. doi: 10.1136\/bcr-2013-009424 (published online first: 22 May)","journal-title":"BMJ Case Rep"},{"issue":"11","key":"8244_CR22","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1212\/01.wnl.0000219042.60538.92","volume":"66","author":"T Schmitz-H\u00fcbsch","year":"2006","unstructured":"Schmitz-H\u00fcbsch T, du Montcel ST, Baliko L, Berciano J, Boesch S, Depondt C, Giunti P, Globas C, Infante J, Kang JS, Kremer B, Mariotti C, Melegh B, Pandolfo M, Rakowicz M, Ribai P, Rola R, Sch\u00f6ls L, Szymanski S, van de Warrenburg BP, D\u00fcrr A, Klockgether T, Fancellu R (2006) Scale for the assessment and rating of ataxia: development of a new clinical scale. Neurology 66(11):1717\u20131720","journal-title":"Neurology"},{"key":"8244_CR23","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1093\/brain\/121.4.589","volume":"121","author":"T Klockgether","year":"1998","unstructured":"Klockgether T, L\u00fcdtke R, Kramer B, Abele M, B\u00fcrk K, Sch\u00f6ls L, Riess O, Laccone F, Boesch S, Lopes-Cendes I, Brice A, Inzelberg R, Zilber N, Dichgans J (1998) The natural history of degenerative ataxia: a retrospective study in 466 patients. Brain 121:589\u2013600","journal-title":"Brain"},{"issue":"11","key":"8244_CR24","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1212\/WNL.0b013e31821043a4","volume":"76","author":"E Brusse","year":"2011","unstructured":"Brusse E, Brusse-Keizer MG, Duivenvoorden HJ, van Swieten JC (2011) Fatigue in spinocerebellar ataxia: patient self-assessment of an early and disabling symptom. Neurology 76(11):953\u2013959","journal-title":"Neurology"},{"issue":"2","key":"8244_CR25","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0022-510X(96)00231-6","volume":"145","author":"P Trouillas","year":"1997","unstructured":"Trouillas P, Takayanagi T, Hallett M, Currier RD, Subramony SH, Wessel K, Bryer A, Diener HC, Massaquoi S, Gomez CM, Coutinho P, Ben Hamida M, Campanella G, Filla A, Schut L, Timann D, Honnorat J, Nighoghossian N, Manyam B (1997) International Cooperative Ataxia Rating Scale for pharmacological assessment of the cerebellar syndrome. The Ataxia Neuropharmacology Committee of the World Federation of Neurology. J Neurol Sci 145(2):205\u2013211","journal-title":"J Neurol Sci"},{"issue":"5","key":"8244_CR26","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1373\/clinchem.2007.099077","volume":"54","author":"J Lu","year":"2008","unstructured":"Lu J, Frank EL (2008) Rapid HPLC measurement of thiamine and its phosphate esters in whole blood. Clin Chem 54(5):901\u2013906","journal-title":"Clin Chem"},{"issue":"2","key":"8244_CR27","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/S1474-4422(14)70321-7","volume":"14","author":"K Reetz","year":"2015","unstructured":"Reetz K, Dogan I, Costa AS, Dafotakis M, Fedosov K, Giunti P, Parkinson MH, Sweeney MG, Mariotti C, Panzeri M, Nanetti L, Arpa J, Sanz-Gallego I, Durr A, Charles P, Boesch S, Nachbauer W, Klopstock T, Karin I, Depondt C, vom Hagen JM, Sch\u00f6ls L, Giordano IA, Klockgether T, B\u00fcrk K, Pandolfo M, Schulz JB (2015) Biological and clinical characteristics of the European Friedreich\u2019s Ataxia Consortium for Translational Studies (EFACTS) cohort: a cross-sectional analysis of baseline data. Lancet Neurol 14(2):174\u2013182","journal-title":"Lancet Neurol"},{"issue":"8","key":"8244_CR28","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1586\/14737175.2014.939173","volume":"14","author":"CJ Strawser","year":"2014","unstructured":"Strawser CJ, Schadt KA, Lynch DR (2014) Therapeutic approaches for the treatment of Friedreich\u2019s ataxia. Expert Rev Neurother 14(8):949\u2013957","journal-title":"Expert Rev Neurother"},{"issue":"10","key":"8244_CR29","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/S1474-4422(07)70220-X","volume":"6","author":"NA Prospero Di","year":"2007","unstructured":"Di Prospero NA, Baker A, Jeffries N, Fischbeck KH (2007) Neurological effects of high-dose idebenone in patients with Friedreich\u2019s ataxia: a randomised, placebo-controlled trial. Lancet Neurol 6(10):878\u2013886","journal-title":"Lancet Neurol"},{"issue":"8","key":"8244_CR30","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1001\/archneurol.2010.168","volume":"67","author":"DR Lynch","year":"2010","unstructured":"Lynch DR, Perlman SL, Meier T (2010) A phase 3, double-blind, placebo-controlled trial of idebenone in friedreich ataxia. Arch Neurol 67(8):941\u2013947","journal-title":"Arch Neurol"},{"issue":"Suppl 1","key":"8244_CR31","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/jnc.12301","volume":"126","author":"C Mariotti","year":"2013","unstructured":"Mariotti C, Nachbauer W, Panzeri M, Poewe W, Taroni F, Boesch S (2013) Erythropoietin in Friedreich ataxia. J Neurochem 126(Suppl 1):80\u201387","journal-title":"J Neurochem"},{"issue":"7","key":"8244_CR32","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1002\/mds.25836","volume":"29","author":"S Boesch","year":"2014","unstructured":"Boesch S, Nachbauer W, Mariotti C, Sacca F, Filla A, Klockgether T, Klopstock T, Sch\u00f6ls L, Jacobi H, B\u00fcchner B, vom Hagen JM, Nanetti L, Manicom K (2014) Safety and tolerability of carbamylated erythropoietin in Friedreich\u2019s ataxia. Mov Disord 29(7):935\u2013939","journal-title":"Mov Disord"},{"issue":"4","key":"8244_CR33","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1002\/ana.24248","volume":"76","author":"M Pandolfo","year":"2014","unstructured":"Pandolfo M, Arpa J, Delatycki MB, Le Quan Sang KH, Mariotti C, Munnich A, Sanz-Gallego I, Tai G, Tarnopolsky MA, Taroni F, Spino M, Tricta F (2014) Deferiprone in Friedreich ataxia: a 6-month randomized controlled trial. Ann Neurol 76(4):509\u2013521","journal-title":"Ann Neurol"},{"issue":"Suppl 1","key":"8244_CR34","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/jnc.12302","volume":"126","author":"JM Gottesfeld","year":"2013","unstructured":"Gottesfeld JM, Rusche JR, Pandolfo M (2013) Increasing frataxin gene expression with histone deacetylase inhibitors as a therapeutic approach for Friedreich\u2019s ataxia. J Neurochem 126(Suppl 1):147\u2013154","journal-title":"J Neurochem"},{"issue":"4","key":"8244_CR35","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1002\/ana.24260","volume":"76","author":"E Soragni","year":"2014","unstructured":"Soragni E, Miao W, Iudicello M, Jacoby D, De Mercanti S, Clerico M, Longo F, Piga A, Ku S, Campau E, Du J, Penalver P, Rai M, Madara JC, Nazor K, O\u2019Connor M, Maximov A, Loring JF, Pandolfo M, Durelli L, Gottesfeld JM, Rusche JR (2014) Epigenetic therapy for Friedreich ataxia. Ann Neurol 76(4):489\u2013508","journal-title":"Ann Neurol"},{"issue":"9942","key":"8244_CR36","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/S0140-6736(14)60382-2","volume":"384","author":"V Libri","year":"2014","unstructured":"Libri V, Yandim C, Athanasopoulos S, Loyse N, Natisvili T, Law PP, Chan PK, Mohammad T, Mauri M, Tam KT, Leiper J, Piper S, Ramesh A, Parkinson MH, Huson L, Giunti P, Festenstein R (2014) Epigenetic and neurological effects and safety of high-dose nicotinamide in patients with Friedreich\u2019s ataxia: an exploratory, open-label, dose-escalation study. Lancet 384(9942):504\u2013513","journal-title":"Lancet"},{"issue":"10","key":"8244_CR37","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/S1474-4422(15)00201-X","volume":"14","author":"S Romano","year":"2015","unstructured":"Romano S, Coarelli G, Marcotulli C, Leonardi L, Piccolo F, Spadaro M, Frontali M, Ferraldeschi M, Vulpiani MC, Ponzelli F, Salvetti M, Orzi F, Petrucci A, Vanacore N, Casali C, Ristori G (2015) Riluzole in patients with hereditary cerebellar ataxia: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 14(10):985\u2013991","journal-title":"Lancet Neurol"},{"issue":"4","key":"8244_CR38","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1097\/CND.0b013e3181910074","volume":"10","author":"TA Zesiewicz","year":"2009","unstructured":"Zesiewicz TA, Sullivan KL, Gooch CL, Lynch DR (2009) Subjective improvement in proprioception in 2 patients with atypical Friedreich ataxia treated with varenicline (Chantix). J Clin Neuromuscul Dis 10(4):191\u2013193","journal-title":"J Clin Neuromuscul Dis"},{"issue":"5","key":"8244_CR39","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1007\/s00415-015-7719-2","volume":"262","author":"EM Yiu","year":"2015","unstructured":"Yiu EM, Tai G, Peverill RE, Lee KJ, Croft KD, Mori TA, Scheiber-Mojdehkar B, Sturm B, Praschberger M, Vogel AP, Rance G, Stephenson SE, Sarsero JP, Stockley C, Lee CY, Churchyard A, Evans-Galea MV, Ryan MM, Lockhart PJ, Corben LA, Delatycki MB (2015) An open-label trial in Friedreich ataxia suggests clinical benefit with high-dose resveratrol, without effect on frataxin levels. J Neurol 262(5):1344\u20131353","journal-title":"J Neurol"},{"issue":"1","key":"8244_CR40","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/mds.23879","volume":"27","author":"C Marelli","year":"2012","unstructured":"Marelli C, Figoni J, Charles P, Anheim M, Tchikviladze M, Vincitorio CM, du Montcel ST, Brice A, Golmard JL, D\u00fcrr A (2012) Annual change in Friedreich\u2019s ataxia evaluated by the Scale for the Assessment and Rating of Ataxia (SARA) is independent of disease severity. Mov Disord 27(1):135\u2013138","journal-title":"Mov Disord"},{"issue":"12","key":"8244_CR41","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1002\/mds.22660","volume":"24","author":"K B\u00fcrk","year":"2009","unstructured":"B\u00fcrk K, M\u00e4lzig U, Wolf S, Heck S, Dimitriadis K, Schmitz-H\u00fcbsch T, Hering S, Lindig TM, Haug V, Timmann D, Degen I, Kruse B, D\u00f6rr JM, Ratzka S, Ivo A, Sch\u00f6ls L, Boesch S, Klockgether T, Klopstock T, Schulz JB (2009) Comparison of three clinical rating scales in Friedreich ataxia (FRDA). Mov Disord 24(12):1779\u20131784","journal-title":"Mov Disord"},{"issue":"Suppl 1","key":"8244_CR42","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/jnc.12318","volume":"126","author":"K B\u00fcrk","year":"2013","unstructured":"B\u00fcrk K, Schulz SR, Schulz JB (2013) Monitoring progression in Friedreich ataxia (FRDA): the use of clinical scales. J Neurochem 126(Suppl 1):118\u2013124","journal-title":"J Neurochem"},{"issue":"1","key":"8244_CR43","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/ane.12141","volume":"129","author":"J Arpa","year":"2014","unstructured":"Arpa J, Sanz-Gallego I, Rodr\u00edguez-de-Rivera FJ, Dom\u00ednguez-Melc\u00f3n FJ, Prefasi D, Oliva-Navarro J, Moreno-Yang\u00fcela M (2014) Triple therapy with deferiprone, idebenone and riboflavin in Friedreich\u2019s ataxia\u2014open-label trial. Acta Neurol Scand 129(1):32\u201340","journal-title":"Acta Neurol Scand"},{"issue":"5","key":"8244_CR44","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1007\/s12311-013-0482-y","volume":"12","author":"J Arpa","year":"2013","unstructured":"Arpa J, Sanz-Gallego I, Rodr\u00edguez-de-Rivera FJ, Dom\u00ednguez-Melc\u00f3n FJ, Prefasi D, Oliva-Navarro J, Moreno-Yang\u00fcela M, Pascual-Pascual SI (2013) Triple therapy with darbepoetin alfa, idebenone, and riboflavin in Friedreich\u2019s ataxia: an open-label trial. Cerebellum 12(5):713\u2013720","journal-title":"Cerebellum"},{"issue":"1","key":"8244_CR45","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/ane.12337","volume":"132","author":"L Seyer","year":"2015","unstructured":"Seyer L, Greeley N, Foerster D, Strawser C, Gelbard S, Dong Y, Schadt K, Cotticelli MG, Brocht A, Farmer J, Wilson RB, Lynch DR (2015) Open-label pilot study of interferon gamma-1b in Friedreich ataxia. Acta Neurol Scand 132(1):7\u201315","journal-title":"Acta Neurol Scand"},{"issue":"1","key":"8244_CR46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12311-010-0212-7","volume":"10","author":"D Velasco-S\u00e1nchez","year":"2011","unstructured":"Velasco-S\u00e1nchez D, Aracil A, Montero R, Mas A, Jim\u00e9nez L, O\u2019Callaghan M, Tondo M, Capdevila A, Blanch J, Artuch R, Pineda M (2011) Combined therapy with idebenone and deferiprone in patients with Friedreich\u2019s ataxia. Cerebellum 10(1):1\u20138","journal-title":"Cerebellum"},{"key":"8244_CR47","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/2053-8871-1-10","volume":"1","author":"I Sanz-Gallego","year":"2014","unstructured":"Sanz-Gallego I, Torres-Aleman I, Arpa J (2014) IGF-1 in Friedreich\u2019s Ataxia\u2014proof-of-concept trial. Cerebellum Ataxias 1:10","journal-title":"Cerebellum Ataxias"},{"issue":"10","key":"8244_CR48","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1007\/s00415-013-7016-x","volume":"260","author":"M Strupp","year":"2013","unstructured":"Strupp M, Teufel J, Habs M, Feuerecker R, Muth C, van de Warrenburg BP, Klopstock T, Feil K (2013) Effects of acetyl-DL-leucine in patients with cerebellar ataxia: a case series. J Neurol 260(10):2556\u20132561","journal-title":"J Neurol"},{"issue":"4","key":"8244_CR49","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s12311-010-0199-0","volume":"9","author":"A Takei","year":"2010","unstructured":"Takei A, Hamada S, Homma S, Hamada K, Tashiro K, Hamada T (2010) Difference in the effects of tandospirone on ataxia in various types of spinocerebellar degeneration: an open-label study. Cerebellum 9(4):567\u2013570","journal-title":"Cerebellum"},{"issue":"3","key":"8244_CR50","doi-asserted-by":"crossref","first-page":"291","DOI":"10.4103\/0366-6999.150087","volume":"128","author":"S Tan","year":"2015","unstructured":"Tan S, Wang RH, Niu HX, Shi CH, Mao CY, Zhang R, Song B, Sun SL, Liu XJ, Hou HM, Liu YT, Gao Y, Fang H, Kong XD, Xu YM (2015) Nerve growth factor for the treatment of spinocerebellar ataxia type 3: an open-label study. Chin Med J (Engl) 128(3):291\u2013294","journal-title":"Chin Med J (Engl)"},{"issue":"2","key":"8244_CR51","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/mds.23423","volume":"26","author":"J Arpa","year":"2011","unstructured":"Arpa J, Sanz-Gallego I, Medina-B\u00e1ez J, Portela LV, Jardim LB, Torres-Aleman I, Saute JA (2011) Subcutaneous insulin-like growth factor-1 treatment in spinocerebellar ataxias: an open label clinical trial. Mov Disord 26(2):358\u2013359","journal-title":"Mov Disord"},{"key":"8244_CR52","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1002\/ana.22526","volume":"70","author":"G Coppola","year":"2011","unstructured":"Coppola G, Burnett R, Perlman S, Versano R, Gao F, Plasterer H, Rai M, Sacc\u00e1 F, Filla A, Lynch DR, Rusche JR, Gottesfeld JM, Pandolfo M, Geschwind DH (2011) A gene expression phenotype in lymphocytes from Friedrich Ataxia patients. Ann Neurol 70:790\u2013804","journal-title":"Ann Neurol"},{"key":"8244_CR53","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1472-6904-12-4","volume":"12","author":"HA Smithline","year":"2012","unstructured":"Smithline HA, Donnino M, Greenblatt DJ (2012) Pharmacokinetics of high-dose oral thiamine hydrochloride in healthy subjects. BMC Clin Pharmacol 12:4","journal-title":"BMC Clin Pharmacol"},{"key":"8244_CR54","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.neuint.2007.03.010","volume":"50","author":"Q Shi","year":"2007","unstructured":"Shi Q, Karuppagounder SS, Xu H, Pechman D, Chen H, Gibson GE (2007) Responses of the mitochondrial alpha-Ketoglutarate dehydrogenase complex to thiamine deficiency may contribute to regional selective vulnerability. Neurochem Int 50:921\u2013931","journal-title":"Neurochem Int"},{"issue":"4","key":"8244_CR55","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/BF02043580","volume":"3","author":"G Uziel","year":"1982","unstructured":"Uziel G, Bottacchi E, Moschen G, Giovanardi-Rossi P, Cardace G, Di Donato S (1982) Pyruvate-dehydrogenase complex in ataxic patients: enzyme deficiency in ataxic encephalopathy plus lactic acidosis and normal activity in Friedreich ataxia. Ital J Neurol Sci 3(4):317\u2013321","journal-title":"Ital J Neurol Sci"},{"issue":"6","key":"8244_CR56","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1212\/WNL.29.6.820","volume":"29","author":"DA Stumpf","year":"1979","unstructured":"Stumpf DA, Parks JK (1979) Friedreich ataxia. II. Normal kinetics of lipoamide dehydrogenase. Neurology 29(6):820\u2013826","journal-title":"Neurology"},{"issue":"1","key":"8244_CR57","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1006\/neur.1996.0004","volume":"5","author":"F Mastrogiacomo","year":"1996","unstructured":"Mastrogiacomo F, LaMarche J, Dozi\u0107 S, Lindsay G, Bettendorff L, Robitaille Y, Schut L, Kish SJ (1996) Immunoreactive levels of alpha-ketoglutarate dehydrogenase subunits in Friedreich\u2019s ataxia and spinocerebellar ataxia type 1. Neurodegeneration 5(1):27\u201333","journal-title":"Neurodegeneration"},{"issue":"4","key":"8244_CR58","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1002\/mds.870110415","volume":"11","author":"L Bettendorff","year":"1996","unstructured":"Bettendorff L, Mastrogiacomo F, LaMarche J, Dozic S, Kish SJ (1996) Brain levels of thiamine and its phosphate esters in Friedreich\u2019s ataxia and spinocerebellar ataxia type 1. Mov Disord 11(4):437\u2013439","journal-title":"Mov Disord"},{"issue":"8","key":"8244_CR59","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1002\/pmic.200701049","volume":"8","author":"R Sutak","year":"2008","unstructured":"Sutak R, Xu X, Whitnall M, Kashem MA, Vyoral D, Richardson DR (2008) Proteomic analysis of hearts from frataxin knockout mice: marked rearrangement of energy metabolism, a response to cellular stress and altered expression of proteins involved in cell structure, motility and metabolism. Proteomics 8(8):1731\u20131741","journal-title":"Proteomics"},{"issue":"4","key":"8244_CR60","doi-asserted-by":"publisher","first-page":"e1000354","DOI":"10.1371\/journal.pbio.1000354","volume":"8","author":"R Shi","year":"2010","unstructured":"Shi R, Proteau A, Villarroya M, Moukadiri I, Zhang L, Trempe JF, Matte A, Armengod ME, Cygler M (2010) Structural basis for Fe-S cluster assembly and tRNA thiolation mediated by IscS protein-protein interactions. PLoS Biol 8(4):e1000354. doi: 10.1371\/journal.pbio.1000354","journal-title":"PLoS Biol"},{"key":"8244_CR61","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/1750-1172-8-83","volume":"8","author":"M Alfadhel","year":"2013","unstructured":"Alfadhel M, Almuntashri M, Jadah RH, Bashiri FA, Al Rifai MT, Al Shalaan H, Al Balwi M, Al Rumayan A, Eyaid W, Al-Twaijri W (2013) Biotin-responsive basal ganglia disease should be renamed biotin-thiamine-responsive basal ganglia disease: a retrospective review of the clinical, radiological and molecular findings of 18 new cases. Orphanet J Rare Dis 8:83. doi: 10.1186\/1750-1172-8-83","journal-title":"Orphanet J Rare Dis"},{"key":"8244_CR62","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1056\/NEJMc0809100","volume":"360","author":"S Kono","year":"2009","unstructured":"Kono S, Miyajima H, Yoshida K, Togawa A, Shirakawa K, Suzuki H (2009) Mutations in a thiamine-transporter gene and Wernicke\u2019s-like encephalopathy. N Engl J Med 360:1792\u20131794","journal-title":"N Engl J Med"},{"issue":"1","key":"8244_CR63","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/ecam\/nek009","volume":"3","author":"D Lonsdale","year":"2006","unstructured":"Lonsdale D (2006) A review of the biochemistry, metabolism and clinical benefits of thiamin(e) and its derivatives. Evid Based Complement Altern Med 3(1):49\u201359","journal-title":"Evid Based Complement Altern Med"},{"issue":"7","key":"8244_CR64","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1136\/jnnp.2007.136630","volume":"79","author":"F Sedel","year":"2008","unstructured":"Sedel F, Challe G, Mayer JM, Boutron A, Fontaine B, Saudubray JM, Brivet M (2008) Thiamine responsive pyruvate dehydrogenase deficiency in an adult with peripheral neuropathy and optic neuropathy. J Neurol Neurosurg Psychiatry 79(7):846\u2013847","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"4","key":"8244_CR65","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1007\/s10545-014-9712-9","volume":"37","author":"G Brown","year":"2014","unstructured":"Brown G (2014) Defects of thiamine transport and metabolism. J Inherit Metab Dis 37(4):577\u2013585. doi: 10.1007\/s10545-014-9712-9","journal-title":"J Inherit Metab Dis"},{"key":"8244_CR66","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S0306-9877(98)90032-9","volume":"51","author":"MI Botez","year":"1998","unstructured":"Botez MI, Botez-Marquard T, Mayer P, Marchand L, Lalonde R, Reader TA (1998) The treatment of spinocerebellar ataxias: facts and hypotheses. Med Hypotheses 51:381\u2013384","journal-title":"Med Hypotheses"},{"key":"8244_CR67","doi-asserted-by":"crossref","first-page":"393","DOI":"10.2174\/156720511795745401","volume":"8","author":"PH Reddy","year":"2011","unstructured":"Reddy PH, Reddy TP (2011) Mitochondria as a therapeutic target for aging and neurodegenerative diseases. Curr Alzheimer Res 8:393\u2013409","journal-title":"Curr Alzheimer Res"},{"key":"8244_CR68","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1177\/089198879300600408","volume":"6","author":"K Meador","year":"1993","unstructured":"Meador K, Loring D, Nichols M, Zamrini E, Rivner M, Posas H, Thompson E, Moore E (1993) Preliminary findings of high-dose thiamine in dementia of Alzheimer\u2019s type. J Geriatr Psychiatry Neurol 6:222\u2013229","journal-title":"J Geriatr Psychiatry Neurol"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-016-8244-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00415-016-8244-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-016-8244-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T19:50:37Z","timestamp":1498333837000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00415-016-8244-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,3]]},"references-count":68,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["8244"],"URL":"https:\/\/doi.org\/10.1007\/s00415-016-8244-7","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,3]]}}}